Position in OMER
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,112,000
+$930,016 QoQ
Shares Held
200,000
+190.7% QoQ
Ownership
0.276%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in OMER Over Time
Shares Held
Position Value (USD)
Derivatives in OMER
reported options exposure · as of Dec 31, 2025CallValue
$3,436,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Polar Asset Management Partners Inc. holds $82,224,376 across 6 Biotechnology names. OMER ranks #5 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
725,000 | $38,222,000 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
1,543,000 | $22,311,780 | |
| 3 | DAWN |
Day One Biopharmaceuticals, Inc.
|
630,410 | $13,515,990 | |
| 4 | TECH |
BIO-TECHNE Corp
|
98,100 | $5,126,706 | |
| 5 | OMER |
Omeros Corp
This page
|
200,000 | $2,112,000 | |
| 6 | RNA |
Atrium Therapeutics, Inc.
|
70,000 | $935,900 |
All Filings in OMER
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,112,000 | 200,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,181,984 | 68,800 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $3,436,000 | 200,000 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $5,633,810 | 1,374,100 | Call | Sole | 2025-12-01 | |
| 2025-09-30 | $6,144,202 | 1,498,586 | Shares | Sole | 2025-12-01 | |
| No filing history on record for this holder in this stock. | ||||||